Description
LUMI-PN EYES is a polynucleotide (PDRN) based skin booster formulated for periocular (under-eye and eye-area) use. Its active component is ultra-pure PDRN at approximately 20 mg/ml, delivering a total of 30 mg PDRN per 1.5 ml syringe, aimed at supporting tissue regeneration in delicate skin zones.¹²³ Rather than functioning as a volumising dermal filler, LUMI-PN EYES works via a regenerative mechanism: PDRN fragments are proposed to stimulate dermal repair, support fibroblast activity, and promote extracellular matrix remodelling potentially improving skin tone, elasticity, hydration, and reducing signs of fatigue or dark circles around the eyes.¹²⁴
What LUMI-PN EYES Is Similar To
LUMI-PN EYES belongs to the class of polynucleotide-based skin boosters rather than traditional hyaluronic acid (HA) fillers. As such, it more closely resembles treatments aimed at skin quality improvement — similar in intent to products like Profhilo (skin-hydrating HA booster) or other PDRN/PN skin-boosters used for skin rejuvenation and texture improvement rather than volumising. Compared to HA fillers — which provide structural volume, contouring, and tissue expansion — LUMI-PN EYES targets tissue regeneration, hydration, and barrier repair without significant volume addition. Its effect profile is oriented toward skin restorative benefits. This comparison is provided for clinical orientation only and does not imply interchangeability.
Treatment Areas / Indications
-
Under-eye and periocular region (delicate eye skin)¹²⁵
-
According to some distributors, treatment may be restricted to under-eye / eye area; broader face/neck use is not specified for this product.¹²³
Usage / Administration (IFU-only section)
-
Injection / application method: According to several UK-supplier descriptions, LUMI-PN EYES is designated for “microneedling / mesotherapy / skin booster” use — not standard deep-injection filler placement.³⁴
-
Injection depth: As per one training document for PDRN boosters, mesotherapy injections are typically delivered at ~4 mm depth.⁵
-
Needle gauge, volume per point, session frequency: Not provided by manufacturer in any publicly accessible documentation.
-
Professional-use disclaimer: Intended for use by qualified aesthetic practitioners. Several retailers explicitly state use is restricted to trained professionals.¹²⁴
Some clinics or practitioners may opt for very superficial serial puncture or microneedling-assisted delivery for periocular boosters; this is not part of the verified public IFU for LUMI-PN EYES.
Ingredient List
-
Polynucleotide (PDRN) 20 mg/ml (total 30 mg per 1.5 ml)¹²³
-
Water (Aqua) solvent / base (implicit in skin booster solutions)⁴
-
Buffer salts / supporting excipients (e.g. sodium salts, stabilisers) — not specified by manufacturer
No hyaluronic acid, lidocaine, or cross-linked gel matrix is declared in publicly available composition data.¹²³
Presentation & Longevity
-
Packaging: 1 × 1.5 ml sterile syringe.¹²³
-
Shelf life / expiry: Not provided by manufacturer in any public listing.
-
Expected duration of effect: As a regenerative skin booster, LUMI-PN EYES does not provide a fixed volumising effect; the duration depends on the skin’s regeneration response and individual factors. No explicit longevity claim is provided in documentation.
Safety Notes / Contraindications
Publicly available product pages do not present a complete IFU-based list of contraindications or warnings for LUMI-PN EYES. Based on standard clinical caution for skin-booster or mesotherapy treatments:
-
Should be administered only by qualified professionals under aseptic conditions.¹²⁴
-
Use is contraindicated in patients with active skin infections, inflammation, open wounds, or compromised skin integrity at the treatment site.
-
Hypersensitivity or allergy to any ingredient (e.g. PDRN, excipients) may contraindicate use.
-
Injection or microneedling in periocular area carries theoretical risks; practitioners must ensure knowledge of local vascular and anatomical structures.
Regulatory Status
-
Public UK distributor pages for LUMI-PN EYES do not clearly state CE-marking or UKCA certification.¹²³⁴
Regulatory classification not specified in public documentation; verify on the product pack or official IFU before use or marketing.
FAQ
Q1: What is PDRN and how does LUMI-PN EYES work?
A1: PDRN (polydeoxyribonucleotide) comprises purified DNA fragments (often from salmon-derived sources) that, when delivered into skin tissue, may stimulate cell repair, promote fibroblast activity, and enhance extracellular matrix remodelling potentially improving collagen synthesis, skin elasticity, hydration and overall skin quality.⁵ LUMI-PN EYES delivers 30 mg of ultra-pure PDRN in a 1.5 ml syringe, aiming to rejuvenate the delicate under-eye skin rather than add volume.¹²³
Q2: Does LUMI-PN EYES act like a traditional dermal filler and add volume?
A2: No — LUMI-PN EYES is not a volumising HA filler. It lacks cross-linked hyaluronic acid or gel carriers; its base is a PDRN aqueous solution, designed for tissue regeneration and skin quality improvement, not structural volume augmentation.¹²³ Therefore, it should not be used where volume or contour correction is desired.
Q3: For which areas is LUMI-PN EYES indicated?
A3: According to supplier documentation, LUMI-PN EYES is intended for the under-eye and periocular region.¹²³ There is no public indication for its use on other facial zones such as cheeks, cheeks, lips, or chin. Use outside the recommended area is not supported by available information.
Q4: What is the recommended method of administration for LUMI-PN EYES?
A4: Public listings describe LUMI-PN EYES as a skin-booster for microneedling or mesotherapy rather than a classical injectable filler.³⁴ One training source suggests mesotherapy injections at ~4 mm depth.⁵ However, no detailed IFU is publicly available specifying needle gauge, injection points, volume per site, or session frequency. Therefore, practitioners must rely on official IFU or distributor instructions before using the product.
Q5: Are the effects and safety of LUMI-PN EYES verified by clinical studies?
A5: As of publicly available information, I found no peer-reviewed clinical studies specifically referencing LUMI-PN EYES. The theoretical mechanism (PDRN-mediated regeneration) draws from general literature on polynucleotides or skin-booster therapies, but evidence for efficacy and long-term safety of this exact product is lacking in the accessible scientific literature. Clinicians should inform patients accordingly and monitor outcomes.
